摘要
炎症性肠病(inflammatoryboweldisease,IBD)是一种病因不明确的慢性非特异性肠道炎性反应,好发于中青年,呈慢性反复性发作,以黏液血便、腹泻、腹痛、消瘦和贫血为主要表现,病程长,并发症严重,复发率高,可致中毒性巨结肠、肠穿孔、肠梗阻、肠出血、癌变,严重影响患者生活质量。IBD主要包括2种疾病类型,
出处
《中华消化杂志》
CAS
CSCD
北大核心
2013年第10期718-720,共3页
Chinese Journal of Digestion
参考文献4
-
1石卉,万军,苏斌斌,肖珑.溃疡性结肠炎367例复发患者5年随访观察[J].中华医学杂志,2010,90(46):3276-3278. 被引量:22
-
2高翔,肖英莲,陈旻湖,杨荣萍,陈白莉,胡品津.硫唑嘌呤治疗活动性克罗恩病的开放性前瞻性研究[J].中华消化杂志,2011,31(3):145-149. 被引量:20
-
3María Josefina Etchevers,Montserrat Aceituno,Miquel Sans.Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease[J].World Journal of Gastroenterology,2008,14(36):5512-5518. 被引量:10
-
4Charles N.Bernstein,Michael Fried,J.H.Krabshuis,Henry Cohen,R.Eliakim,Suleiman Fedail,Richard Gearry,K.L.Goh,Saheed Hamid,Aamir Ghafor Khan,A.W.LeMair,Malfertheiner,Qin Ouyang,J.F.Rey,Ajit Sood,Flavio Steinwurz,Ole O.Thomsen,Alan Thomson,Gillian Watermeyer,杨钊斌,杨川华,钱本余.2010年世界胃肠病学组织关于炎症性肠病诊断和治疗的实践指南[J].胃肠病学,2010,15(9):548-558. 被引量:103
二级参考文献65
-
1[1]Scaldaferri F,Fiocchi C.Inflammatory bowel disease:progress and current concepts of etiopathogenesis.J Dig Dis 2007; 8:171-178
-
2[2]Cosnes J,Nion-Larmurier I,Beaugerie L,Afchain P,Tiret E,Gendre JP.Impact of the increasing use of mmunosuppressants in Crohn's disease on the need for intestinal surgery.Gut 2005; 54:237-241
-
3[3]Dubinsky MC.Azathioprine,6-mercaptopurine in inflammatory bowel disease:pharmacology,efficacy,and safety.Clin Gastroenterol Hepatol 2004; 2:731-743
-
4[4]Siegel CA,Sands BE.Review article:practical management of inflammatory bowel disease patients taking immunomodulators.Aliment Pharmacol Ther 2005; 22:1-16
-
5[5]Su C,Lichtenstein GR.Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.Gastroenterol Clin North Am 2004; 33:209-234,viii
-
6[6]Sandborn W,Sutherland L,Pearson D,May G,Modigliani R,Prantera C.Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease.Cochrane Database Syst Rev 2000; CD000545
-
7[7]Pearson DC,May GR,Fick G,Sutherland LR.Azathioprine for maintaining remission of Crohn's disease.Cochrane Database Syst Rev 2000;CD000067
-
8[8]Present DH,Meltzer SJ,Krumholz MP,Wolke A,Korelitz BI.6-Mercaptopurine in the management of inflammatory bowel disease:short-and long-term toxicity.Ann Intern Med 1989; 111:641-649
-
9[9]Gisbert JP,Gonzelez-Lama Y,Mate J.Thiopurine-induced liver injury in patients with inflammatory bowel disease:a systematic review.Am J Gastroentero12007; 102:1518-1527
-
10[10]Masunaga Y,Ohno K,Ogawa R,Hashiguchi M,Echizen H,Ogata H.Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease.Ann Pharmacother 2007; 41:21-28
共引文献151
-
1钱家鸣,杨红.中国炎症性肠病研究现状和展望[J].中华炎性肠病杂志(中英文),2017,1(1):2-4. 被引量:21
-
2中华医学会消化病学分会炎症性肠病学组,胡品津,钱家鸣.建立全国通用的炎症性肠病诊治过程的关键性质量控制指标的共识意见[J].中华炎性肠病杂志(中英文),2017,1(1):12-19. 被引量:21
-
3Giovanni C Actis,Rinaldo Pellicano,Mario Rizzetto,Muhammad Ayoubi,Nicola Leone,Gianfranco Tappero,Paola Pazienza,Floriano Rosina.Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease[J].World Journal of Gastroenterology,2009,15(12):1420-1426.
-
4徐妹琪,钟捷,程时丹,王立夫,张曙,张晨莉,陈明.双气囊内镜在小肠克罗恩病疗效随访中的应用价值初探[J].中华消化内镜杂志,2009,26(9):467-470. 被引量:1
-
5刘梅,刘南植.生物制剂治疗炎症性肠病的应用原则和评价[J].内科急危重症杂志,2010,16(5):234-236. 被引量:2
-
6林军,向琴.重度克罗恩病的内科治疗[J].医学新知,2011,21(1):12-14. 被引量:1
-
7向琴,林军.重度克罗恩病的内科治疗[J].临床药物治疗杂志,2011,9(4):40-44. 被引量:1
-
8李瑾,夏冰,邓长生.成人炎症性肠病的规范化诊断-全球实践指南解读[J].医学新知,2011,21(4):285-289. 被引量:2
-
9齐海鑫,徐伟祥.药物治疗溃疡性结肠炎进展[J].现代中西医结合杂志,2011,20(30):3900-3902. 被引量:8
-
10吴小平,张文婷.免疫抑制药在炎性肠病治疗中的作用[J].临床药物治疗杂志,2011,9(5):16-21. 被引量:4
同被引文献26
-
1陈灏珠.实用内科学[M].北京:人民卫生出版社,2006:1834,1918.
-
2Contreras-Ruiz L, Schulze U, Garda-Posadas L, et al. Structural and functional alteration of corneal epithelial barrier under inflammatory conditions [J]. Curr Eye Res, 2012,37(11), 971-981. DOI, 10.3109/02713683.2012.700756.
-
3Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system [J]. Nat Rev Drug Discov, 2014, 13(1) ..21-38. DOI.. 10. 1038/nrd4176.
-
4Yamada S, Koyama T, Noguchi H, et al. Marine hydroquinone zonarol prevents inflammation and apoptosis in dextran sulfate sodium-induced mice ulcerative colitis[J/OL]. PLoS One, 2014, 9(11)z e113509[2014-11-19] http:// journals, plos. org/plosone/article? id ~ 10. 1371/journal. pone. 0113509. DOI.. 10. 1371/journal. pone. 0113509.
-
5Oficjalska K, Raverdeau M, Aviello G, et al. Protective role for caspas-11 during acute experimental murine colitis[J].J Immunol, 2015,194(3)1252-1260.
-
6Wolk K, Witte E, Witte K, et al. Biology of interleukin-22 [J]. Semin Immunopathol, 2010, 32 (1) : 17-31. DOI.. 10. 1007/s00281-009-0188-x.
-
7Sun X, Chalmers L, Fu X, et al. A molecular link between interleukin 22 and intestinal mucosal wound healing [J]. Adv Wound Care (New Rochelle), 2012,1(6) : 231-237. 13OI= 10. 1089/wound. 2011. 0334.
-
8Ouyang W. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease [J].Cytokine Growth Factor Rev, 2010,21(6) :435-441. DOI:10. 1016/j. cytogft, 2010.10.007.
-
9Zhao J, Shi P, Sun Y, et al. DHA protects against experimental colitis in IL-10-deficient mice associated with the modulation of intestinal epithelial barrier function [J].Br J Nutr, 2015, 114 ( 2 ): 181-188. DOI: 10. 1017/ S0007114515001294.
-
10Oh SY, Cho KA, Kang JL,et al. Comparison of experimental mouse models of inflammatory bowel disease[J]. Int J Mol Med, 2014,33(2) :333-340. DOIz 10. 3892/ijmm. 2013. 1569.
引证文献3
-
1农辉,黄婧渝,黄雪,谭至柔,覃蒙斌,李卉,张钰琴.白细胞介素-22对小鼠实验性结肠炎肠黏膜闭合蛋白的影响[J].中华消化杂志,2016,36(6):420-422. 被引量:1
-
2李远洪.双歧杆菌联合康复新液治疗重度溃疡性结肠炎的疗效观察[J].中国当代医药,2016,23(20):138-140. 被引量:5
-
3张明,王新颖.组织愈合在炎症性肠病诊治中的应用[J].中华消化杂志,2017,37(1):68-70. 被引量:6
二级引证文献12
-
1方静,陈江,彭君伟,李红林,姜程帆,金玉.薏苡附子败酱散对小鼠急性期溃疡性结肠炎肠黏膜的修复作用[J].上海中医药大学学报,2018,32(3):67-71. 被引量:17
-
2王琳,陈思敏.康复新液辅助治疗溃疡性结肠炎的研究进展[J].中药与临床,2017,8(5):63-66. 被引量:4
-
3李辉标,陈新林,陈慕媛,丘振文,李得堂,唐洪梅.康复新液联用益生菌治疗溃疡性结肠炎Meta分析[J].辽宁中医杂志,2018,45(10):2037-2041. 被引量:5
-
4刘欣欣.双歧杆菌三联活菌和英夫利昔单抗联合治疗中重度溃疡性结肠炎的效果分析[J].中国医药指南,2019,17(11):133-134. 被引量:4
-
5鲁霞,罗黎.炎症性肠病患者Th22细胞亚群和IL-22水平变化及其临床意义[J].中国微生态学杂志,2019,31(10):1203-1206. 被引量:18
-
6张明,蒋崇慧.透壁愈合作为评估克罗恩病缓解指标的应用进展[J].中国全科医学,2020,23(30):3884-3887. 被引量:2
-
7孙庆申,罗钦文,许艳玲.双歧杆菌及其产品缓解肠炎症状的研究进展[J].乳业科学与技术,2020,43(4):29-33. 被引量:3
-
8李红琳,薛怡,陈江,梁国强.基于16S rDNA测序技术分析薏苡附子败酱散对急性溃疡性结肠炎小鼠肠道菌群的影响[J].中国微生态学杂志,2021,33(12):1365-1373. 被引量:10
-
9刘得超,郭添弟,吴耿兴,李国华,胡秋根.MR及CT小肠造影在克罗恩病诊断及疗效评估中的价值[J].中国CT和MRI杂志,2022,20(9):141-143. 被引量:12
-
10中国医师协会消化医师分会,杨云生,张琳,陈萦晅,黄永坤,靳英辉,江米足,李景南,李在玲,田杨,田德安,王蔚虹,夏璐,熊理守,郑跃杰.双歧杆菌四联活菌片在消化系疾病临床应用的专家共识[J].中华内科杂志,2024,63(10):927-960.
-
1王颖,刘畅,王炳元.溃疡性结肠炎合并中毒性巨结肠1例报告并文献复习[J].中国误诊学杂志,2008,8(5):1248-1249. 被引量:3
-
2魏睦新.溃疡性结肠炎,需要长期治疗[J].祝您健康,2011(1):19-20.
-
3徐平如,周锋.益生菌联合美沙拉嗪对炎症性肠病治疗的临床研究[J].中外医疗,2010,29(4):7-8. 被引量:10
-
4冉志华,沈骏.炎症性肠病治疗中的新概念[J].胃肠病学,2009,14(2):69-73. 被引量:4
-
5乌兰图雅,韩格日乐.溃疡性结肠炎的诊断和治疗[J].内蒙古民族大学学报,2010,16(2):117-118. 被引量:8
-
6张小春.丹参川芎嗪注射液治疗炎症性肠病疗效分析[J].中国医药指南,2012,10(16):285-286.
-
7惠秀丽,荣加.1例溃疡性结肠炎并发中毒性巨结肠患者的护理[J].中华现代护理杂志,2009,15(2):171-172.
-
8涂必红,刘铭.氧氟沙星致肠炎并中毒性巨结肠1例[J].中国误诊学杂志,2011,11(7):1736-1736.
-
9黄映娇.重症克罗恩病诊治进展[J].临床荟萃,2007,22(2):139-141. 被引量:2
-
10刘颂,任建安.克罗恩病治疗的新目标:黏膜愈合[J].中华外科杂志,2012,50(12):1139-1142. 被引量:1